Ajinomoto completed the acquisition of Forge Biologics for $545m.

Ajinomoto, a Japanese multinational food and biotechnology corporation, completed the acquisition of Forge Biologics, a US based manufacturer of genetic medicines, for $545m. “Forge’s unparalleled expertise in gene therapy development and manufacturing will be a transformative addition to our core growth area of Healthcare as part of our ASV Initiatives 2030 Roadmap. Forge brings to Ajinomoto an entirely new capability that will vitally enhance our Bio-Pharma Services business and help create new value through innovative solutions for communities and society,” Yasuyuki Otake, Bio-Pharma Services Department of Ajinomoto Corporate Executive and General Manager.